Introduction {#S1}
============

Ghrelin was first identified in rat stomach as an endogenous ligand for the growth hormone secretagogue receptor (GHS-R) ([@B1]). Ghrelin has since been identified in all vertebrate classes; fish ([@B2]--[@B3][@B4]), birds ([@B5]), amphibians ([@B6]), reptiles ([@B7]), mammals ([@B1], [@B8]), as well as sharks ([@B9]). All ghrelins identified thus far are uniquely and primarily acylated by octanoic or decanoic acid on the third amino acid from the N-terminus ([@B10], [@B11]). However, a variety of other acyl-forms of ghrelins (*n*-hexanoic and *n*-non-anoic acid) and unsaturated *n*-octanoic and *n*-decanoic isoforms of ghrelin have been identified ([@B5], [@B12], [@B13]). The acyl modification is necessary for ghrelins biological action ([@B10]). Indeed, the first seven amino acid residues on the N-terminus are highly conserved across vertebrates and are known as the "active core" ([@B11], [@B14]) suggesting an evolutionary conserved physiological role of ghrelin. Unlike tetrapod ghrelins, fish ghrelins possess an amide modification on the C-terminus ([@B11]). Ghrelin is predominately synthesized in the stomach and is also expressed in a variety of other tissues such as small and large intestine, pancreas, liver, hypothalamus, telencephalon, pituitary, gonads, kidneys, gills, adipose tissue, and many others ([@B14], [@B15]).

The biological actions of ghrelin are mediated by the GHS-R, which codes for two separate transcripts, GHS-R1a and GHS-R1b ([@B16]). GHS-R1a is a seven transmembrane domain G-protein coupled receptor. This receptor is responsive to both synthetic growth hormone secretagogues and ghrelin in regulating several neuroendocrine, metabolic, and non-endocrine actions ([@B15]). The GHS-R1b transcript is shorter than the GHS-R1a isoform due to the intron not being spliced out thus disrupting the normal reading frame and resulting in a "non-functional" receptor with five transmembrane domains ([@B11], [@B17]). GHS-R1b has been suggested to act as a dominant-negative mutant. The formation of GHS-R1a/GHS-R1b heterodimer facilitates the translocation of GHS-R1a to the nucleus decreasing the constitutive signaling of GHS-R1a, thus inhibiting ghrelin's actions ([@B18]). Both isoforms are found in a variety of endocrine and non-endocrine tissues such as hypothalamus and a variety of other brain regions, pituitary, liver, lung, heart, muscle, kidney, and gonads ([@B19]). Two GHS-R isoforms have been identified in the black seabream ([@B20]). We have recently identified two GHS-R isoforms in the tilapia and determined their tissue distribution ([@B21], [@B22]).

The existence of ghrelin, GHS-R1a and GHS-R1b in fish suggests that the fundamental biological functions of ghrelin are conserved across vertebrate species ([@B19], [@B20]). In spite of the fact that all vertebrates possess multiple forms of ghrelin, nearly all of our understanding about ghrelin's biological actions has come from studies using the ghrelin-C8, thus leaving a huge gap in our understanding of ghrelin biology. This mini review focuses on the differential effects of ghrelin-C8 and ghrelin-C10 in tilapia. For more general information on the structure and function of ghrelin within vertebrates the reader is referred to the following review papers ([@B11], [@B14], [@B23], [@B24]).

Differential Roles of Ghrelin-C8 and Ghrelin-C10 in Tilapia {#S2}
===========================================================

We have identified two forms of ghrelin in the Mozambique tilapia (*Oreochromis mossambicus*) stomach ([@B4]). They exhibit 100% amino acid identity with each other, the difference being the acyl modification (*n*-octanoic or *n*-decanoic) on Ser^3^. The major form of tilapia ghrelin possesses an *n*-decanoic (ghrelin-C10) modification ([@B4]). Multiple isoforms of ghrelin have been identified in other fish species, as observed in other vertebrates. Four isoforms of ghrelin have been identified in rainbow trout ([@B2]) and 11 isoforms of ghrelin have been identified in goldfish ([@B25]). In the chicken ([@B5]), ghrelin-C8 and ghrelin-C10 were isolated in similar amounts, whereas in goldfish ([@B25]), eel ([@B3]), bullfrog ([@B26]), and humans ([@B27]) ghrelin-C8 is the major form. Both acylated modifications are essential for receptor binding ([@B28]) and ghrelin transport across the blood-brain barrier ([@B29]).

Since its original discovery as a potent growth hormone secretagogue, ghrelin has been shown to be involved in a variety of neuroendocrine, metabolic, and non-endocrine functions that include, but not limited to, orexigenic activity, cardiovascular, gastrointestinal, pancreatic, and lipogenic and glucogenic actions ([@B15], [@B16], [@B23], [@B30]). In spite of the fact that all vertebrates studied to date possess multiple forms of ghrelin, nearly all of the published work has focused on the biological functions of ghrelin-C8 and des-acyl ghrelin. Hosoda et al. ([@B27]) have demonstrated that ghrelin-C8 and ghrelin-C10 exhibit the same potency to increase (Ca^2+^) levels in CHO cells expressing rat GHS-R1a as well as stimulate GH release in rats. In goldfish des-acyl ghrelin was shown to attenuate the orexigenic actions of ghrelin-C8, but had no effect on food intake when administered alone ([@B31]). Notwithstanding, since des-acyl ghrelin has been shown to exhibit some biological functions \[e.g., stimulate adipogenesis and cardioprotective actions ([@B32], [@B33])\], that the biological role − beyond stimulating GH release − of the other ghrelin forms have not been further investigated.

We have shown in tilapia that ghrelin-C8 and ghrelin-C10 appear to exhibit differential biological functions ([@B30]). Ghrelin-C10 was more potent than ghrelin-C8 in stimulating GH release from the tilapia pituitary, yet neither form altered pituitary GH mRNA expression levels ([@B21]). Both forms equally increased liver IGF-1 mRNA expression, but ghrelin-C8 was more potent than ghrelin-C10 in increasing liver growth hormone receptor mRNA expression in tilapia ([@B21]). Tilapia treated with ghrelin-C10 for 21 days (via osmotic pumps) exhibited a significant increase in food intake and body weight; ghrelin-C8 had no effect. The increase in body weight was likely a result of increased adiposity in liver and muscle tissue induced by ghrelin-C10 ([@B34]). Ghrelin-C8 has been shown to stimulate adiposity in rat bone marrow ([@B33]).

Brain neuropeptide Y (NPY) mRNA expression levels were significantly elevated 4 and 8 h following ghrelin-C10, not ghrelin-C8, injection in tilapia ([@B30]). In goldfish, the orexigenic actions of ghrelin have been shown to be mediated by the NPY pathway ([@B35]), thus suggesting a similar mechanism of control in tilapia. In spite of the orexigenic actions of NPY in vertebrates ([@B36]), we have not observed an acute increase in food intake following either ghrelin-C8 or ghrelin-C10 treatment (unpublished observations). In rainbow trout, ghrelin-C8 treatment has been shown to have no effect on food intake ([@B37]), increase food intake ([@B38]), and inhibit food intake ([@B37]). In goldfish, two forms of octanoylated ghrelin (12- and 17-amino acid residues) stimulated food intake, whereas des-acylated ghrelin17 had no effect ([@B25]). Ghrelin-C8 treatment has routinely been shown to stimulate food intake in mammals ([@B24], [@B39]). However, studies using ghrelin (*ghrl*^−/−^) knockout models ([@B40], [@B41]) suggest that ghrelin's role in stimulating food intake is secondary to its maintenance of metabolic energy balance ([@B16], [@B42]). The use of *ghrl*^−/−^ models provides a unique opportunity to investigate the differential roles of the multiple forms of ghrelin.

In tilapia, only ghrelin-C8 significantly elevated plasma glucose levels 4 and 8 h post intraperitoneal injection ([@B30]). In rainbow trout ghrelin-C8 stimulated glucokinase (GK) and pyruvate kinase activity, as well as increased the mRNA expression levels of glucose transporter-2 and *GK* in different regions of the brain, without altering plasma glucose levels ([@B43]). These data suggest that ghrelin-C8, in tilapia and rainbow trout, may play a role in central glucose-sensing as well as in glucose metabolism in fish as observed in mammals ([@B44]). Des-acyl ghrelin had no effect on plasma glucose or insulin levels in healthy humans, but counteracted the actions of ghrelin-C8 on glucose and insulin levels ([@B45]). This indicates that des-acyl ghrelin possesses metabolic functions in mammals ([@B33], [@B45]). These data lend support to the hypothesis that the other acyl-forms of ghrelin may exhibit distinct functions from that of *n*-octanoylated ghrelin. Recently, we have observed that ghrelin-C8 reversed the negative effects of cortisol on the mRNA expression levels of the glucocorticoid receptor (GR) and GHS-R1a-LR in the hypothalamus of tilapia (Figures [1](#F1){ref-type="fig"}A,B, respectively). These data suggest that ghrelin-C8 may be playing a role in counteracting the negative effects of chronic stress and/or stress recovery in tilapia. We have previously observed differential regulation of the GHS-R mRNA isoforms in tilapia ([@B46], [@B47]). Further studies are needed to elucidate the biological significance of the different expression patterns of the GHS-Rs. Taken together, our data in tilapia clearly shows that ghrelin-C8 and ghrelin-C10 exhibit distinct, yet complimentary actions directed toward maintaining metabolic balance within the animal. Our laboratory is currently investigating the direct effects of ghrelin-C8 and ghrelin-C10 on neuropeptide mRNA expression patterns using brain tissue culture methods and proteomic and metabolic approaches.

![**Sexually mature male and female tilapia were surgically implanted with a micro-osmotic pump into the IP cavity containing either saline (control), 100 μg/ml of ghrelin-C8, or 100 μg/ml of ghrelin-C10 ([@B34])**. The calculated rate of release at 24°C was 13 ng/h for 32 days. Twenty-four hours following the surgery fish were fed a control diet or cortisol-laden feed \[500 mg/kg feed; ([@B48])\] for 21 days twice a day. Upon termination of the experiment brain sections were collected, RNA was extracted and reversed transcribed into cDNA. Relative mRNA expression levels were determined by qPCR. Ghrelin-C8 treatment significantly reversed the inhibitory effects of cortisol on GR mRNA expression levels in the hypothalamus **(A)**. Ghrelin-C8 treatment partially reversed the stimulatory effect cortisol exhibited on hypothalamic GHS-R-1a-LR mRNA expression levels **(B)**. mRNA data are presented as relative to saline control feed group. Columns with different letters are significantly different at *P* \< 0.05, *n* = 10--12.](fendo-04-00118-g001){#F1}

Conclusion {#S3}
==========

To date, all vertebrates produce multiple forms of ghrelin. There are reports that des-acyl ghrelin exhibits biological functions in mammals ([@B32], [@B33]) and that both ghrelin-C8 and ghrelin-C10 simulate GH release in rats ([@B27]), suggesting that the other acyl-forms of ghrelin likely exhibit biological functions. In tilapia, both ghrelin-C8 and ghrelin-C10 exert distinct biological actions that appear to be directed toward maintenance of metabolic balance. It is not clear what is the mechanism underlying the different biological effects of ghrelin-C8 and ghrelin-C10. A possible hypothesis is that a third GHS-R-isoform that exhibits higher affinity toward ghrelin-C10 exists or that ghrelin-C10 binds non-specifically to a related receptor.
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